Sorrento acquires lymphatic delivery technology platform from Kimberly-Clark
05 July 2018
Sorrento Therapeutics has acquired Kimberly-Clark’s Sofusa lymphatic delivery technology platform for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors like anti-PD-1, CTLA4, CD47 antibodies and other I-O antibodies.
Kimberly-Clark's Sofusa technology consists of proprietary nano-structured microneedles designed to access the lymphatic capillaries just below the epidermis. In a recent Phase I human study, the Sofusa system has successfully demonstrated the ability to precisely tune the pharmacokinetic profile of sumatriptan to give both rapid onset and an extended treatment duration for the acute treatment of migraine.
Sorrento chief medical officer Jerry Zeldis said: “Delivering higher drug concentrations via the lymphatics could provide more direct and sustained exposure to therapeutic targets known to modulate immune responses. We believe this has the potential to result in an improved safety and efficacy profile for checkpoint inhibitors and anti-inflammatory agents. Sorrento is now well positioned to becoming a leader in the immunotherapy field and fulfill our mission to develop best-in-class antibodies for patients.”
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Recent News
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Read
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Read
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Read
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.